JPWO2023204259A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023204259A5
JPWO2023204259A5 JP2024505170A JP2024505170A JPWO2023204259A5 JP WO2023204259 A5 JPWO2023204259 A5 JP WO2023204259A5 JP 2024505170 A JP2024505170 A JP 2024505170A JP 2024505170 A JP2024505170 A JP 2024505170A JP WO2023204259 A5 JPWO2023204259 A5 JP WO2023204259A5
Authority
JP
Japan
Prior art keywords
salt
formula
compound represented
solvate
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024505170A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023204259A1 (https=
JP7565132B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/015683 external-priority patent/WO2023204259A1/ja
Publication of JPWO2023204259A1 publication Critical patent/JPWO2023204259A1/ja
Publication of JPWO2023204259A5 publication Critical patent/JPWO2023204259A5/ja
Application granted granted Critical
Publication of JP7565132B2 publication Critical patent/JP7565132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024505170A 2022-04-20 2023-04-19 がんの治療又は予防用医薬 Active JP7565132B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022069320 2022-04-20
JP2022069320 2022-04-20
EP22207829.7 2022-11-16
EP22207829 2022-11-16
PCT/JP2023/015683 WO2023204259A1 (ja) 2022-04-20 2023-04-19 がんの治療又は予防用医薬

Publications (3)

Publication Number Publication Date
JPWO2023204259A1 JPWO2023204259A1 (https=) 2023-10-26
JPWO2023204259A5 true JPWO2023204259A5 (https=) 2024-04-01
JP7565132B2 JP7565132B2 (ja) 2024-10-10

Family

ID=88419939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505170A Active JP7565132B2 (ja) 2022-04-20 2023-04-19 がんの治療又は予防用医薬

Country Status (6)

Country Link
US (1) US20250262194A1 (https=)
EP (1) EP4512401A4 (https=)
JP (1) JP7565132B2 (https=)
CN (1) CN119031911A (https=)
TW (1) TW202404586A (https=)
WO (1) WO2023204259A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来(成都)科技股份有限公司 芳香酰肼类衍生物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230523T1 (hr) 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
JP2021063014A (ja) 2019-10-10 2021-04-22 国立大学法人 東京大学 白血病治療薬
WO2021076655A1 (en) * 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
WO2022018875A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
CN115803024B (zh) * 2020-07-22 2025-01-10 中外制药株式会社 包含芳基酰胺衍生物的组合物
BR112023025916A2 (pt) * 2021-06-09 2024-02-27 Chugai Pharmaceutical Co Ltd Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção

Similar Documents

Publication Publication Date Title
JP2020515578A5 (https=)
ES2252519T3 (es) Acido valproico para el tratamiento de cancer de mama, cancer de colon, cancer de cabeza y cuello, carcinoma de celulas pequeñas de pulmon y leucemia, en combinacion con radioterapia.
US20210161837A1 (en) Methods for treating cancer with rorgamma inhibitors
JP6557744B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2020510662A5 (https=)
JP2024075668A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
Hassan et al. New life for immunotoxin cancer therapy
JP2018504418A5 (https=)
JPWO2021085653A5 (https=)
US20130274281A1 (en) Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
JP2009501800A5 (https=)
JP2017031160A5 (https=)
JP2021502423A5 (https=)
US20180222983A1 (en) Methods, compositions, and kits for treatment of cancer
TW202537643A (zh) 抗體-藥物結合物之用途
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
JP2021503915A5 (https=)
JPWO2023204259A5 (https=)
Couto et al. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines
JPWO2021260579A5 (https=)
JP2018524361A5 (https=)
JP2022169780A5 (https=)
JP7750884B2 (ja) HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
JP2015518053A5 (https=)
TW201300105A (zh) 治療頭頸鱗狀細胞癌之相乘藥物組合物